Department of Pulmonology, STZ Centre of Excellence for Asthma, COPD and Respiratory Allergy, Franciscus & Vlietland, Rotterdam, The Netherlands; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Transylvania University, Brasov, Romania.
J Allergy Clin Immunol Pract. 2024 Jan;12(1):23-30. doi: 10.1016/j.jaip.2023.11.031. Epub 2023 Nov 25.
Allergen immunotherapy is a disease-modifying treatment for IgE-mediated allergies reducing disease burden and symptoms in patients with allergic rhinitis, with or without asthma. The growing evidence that allergen immunotherapy also has the potential to facilitate achieving asthma control in patients with allergic asthma resulted in its acknowledgment by international bodies (Global Initiative for Asthma and European Academy of Allergy and Clinical Immunology) as add-on treatment for mild/moderate asthma. Although there have been promising developments in biomarkers for patient selection and for allergen immunotherapy efficacy evaluation in patients with asthma, a lot more data are still required.
变应原免疫治疗是一种针对 IgE 介导的过敏反应的疾病修正治疗，可减轻变应性鼻炎患者（无论是否伴有哮喘）的疾病负担和症状。越来越多的证据表明，变应原免疫治疗也有可能促进变应性哮喘患者实现哮喘控制，因此被国际组织（全球哮喘倡议和欧洲过敏与临床免疫学会）认可为轻度/中度哮喘的附加治疗方法。尽管在哮喘患者的患者选择和变应原免疫治疗疗效评估的生物标志物方面取得了有希望的进展，但仍需要更多的数据。
